Janssen
Pfizer/Janssen Alzheimer’s drug dropped after failure
August 7, 2012Research and Development, Sales and Marketing Alzheimer's, Janssen, Pfizer, bapineuzumab
Pfizer and Janssen have decided to drop their investigational Alzheimer’s drug bapineuzumab after it failed a second late-stage study. The …
Janssen launches drug reminder service ‘Care4Today’
July 26, 2012Medical Communications Care4Today, Janssen, digital
Janssen has launched a new digital service designed to help patients remember to take their medication. Care4Today Mobile Adherence is …
Speedy approval for Onyx’ multiple myeloma drug
July 24, 2012Research and Development, Sales and Marketing FDA, Janssen, Kyprolis, Onyx, Takeda, Velcade
Onyx’ Kyprolis has gained an accelerated approval by the FDA to treat patients with late-stage multiple myeloma. Kyprolis (carfilzomib), a …
Pfizer and Janssen’s Alzheimer’s drug fails
July 24, 2012Research and Development, Sales and Marketing Alzheimer's, Janssen, Pfizer, bapineuzumab
Pfizer and Janssen’s investigational Alzheimer’s drug bapineuzumab is no better than placebo, according to a new study. The Phase III …
Janssen buys into regenerative diabetes portfolio
July 11, 2012Research and Development, Sales and Marketing CureBeta, Evotec, Janssen, diabetes
Janssen has licensed a portfolio of drugs designed to regenerate insulin-producing beta cells. Janssen will receive exclusive access to a …
Priority review for Xarelto’s new indications
July 10, 2012Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Boehringer, Eliquis, FDA, Janssen, Pradaxa, Xarelto
Xarelto is to be given a FDA fast-track review for a range of anti-blood clotting uses. Xarelto (rivaroxaban) gained its …
Janssen submits tuberculosis pill to FDA
July 4, 2012Research and Development, Sales and Marketing Bedaquiline, FDA, J&J, JJ, Janssen, tuberculosis
Janssen has submitted its investigational tuberculosis pill bedaquiline for review by the FDA. The firm is seeking a licence for …
NICE final yes for Zytiga and Tarceva
June 27, 2012Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga
In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …
Janssen looks to broaden Zytiga licence
June 18, 2012Sales and Marketing Cancer, Janssen, NICE, Provenge, Zytiga, prostate
Janssen is looking to broaden the licence for its prostate cancer pill Zytiga. Zytiga currently has a US and European …
Working Life: Jane Griffiths
June 11, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Working Life, brett wells, jane griffiths
After completing her PhD in Biochemistry at the University of Aberystwyth in 1982, Jane worked her way up the Johnson …
UK Prix Galien shortlist announced
May 30, 2012Business Services, Medical Communications, Research and Development, Sales and Marketing Bayer, Janssen, Xarelto, awards, prix galien
The UK award for the most innovative new drug has been moved a step closer with the release of a …
Public-private alliance to discover new antibiotics
May 25, 2012AstraZeneca, EFPIA, GSK, Janssen, Sanofi, antibiotic, bacterial infection
A Europe-wide public-private partnership is to put €224m (£180m) into finding new antibiotics for all manner of bacterial infections such …
Two new hep C pills recommended by NICE
April 25, 2012Sales and Marketing Incivo, Janssen, MSD, NICE, Victrelis, hep C
NICE has given its final recommendation for two new hepatitis C pills in an expedited review. Janssen’s Incivo (telaprevir) and …
J&J fined after ‘lying to patients for profit’
April 16, 2012Medical Communications, Sales and Marketing J&J, JJ, Janssen, Risperdal, US
A US judge has slapped a $1.19 billion fine on Johnson & Johnson after it was found to be downplaying …
Janssen to remove its Psoriasis 360 Facebook page
March 28, 2012Medical Communications Facebook, Janssen, PM Soc, Psoriasis 360
Janssen has decided to take down its award-winning Psoriasis 360 page on Facebook, citing an increasing amount of troublesome comments. …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
